Antibody response of pneumococcal vaccine: Need for booster dosing?

International Journal of Antimicrobial Agents

Volumn 14, Issue 2, 2000, Pages 107-112

  Mufson, Maurice A ^a  

^a MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody; Booster; Pneumococcus; Serotype; Vaccine

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

AGE; ANTIBODY RESPONSE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH RISK POPULATION; HUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; REVACCINATION; REVIEW; SEROTYPE; STREPTOCOCCUS INFECTION;

EID: 0034060653     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(99)00167-3     Document Type: Article

References (49)

1. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly. Rep. 46:1997;1-24.
2. Austrian R. Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention. Rev. Infect. Dis. 3:1981;S1-S17.
3. Austrian R. The Jeremiah Metzger lecture: of gold and pneumococci: a history of pneumococcal vaccines in South Africa. Trans. Am. Clin. Climatol. Assoc. 89:1977;141-161.
4. Fedson D.S., Shapiro E.D., LaForce F.M., Mufson M.A., Musher D.M., Spika J.S. et al. Pneumococcal vaccine after 15 years of use - another view. Arch. Intern. Med. 154:1994;2531-2535.
5. Austrian R., Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann. Intern. Med. 60:1964;759-776.
6. Mufson M.A., Kruss D.M., Wasil R.E., Metzger W.I. Capsular types and outcome of bacteremic pneumococcal disease in the antibiotic era. Arch. Intern. Med. 134:1974;505-510.
7. Mufson M.A. Pneumococcal infections. J. Am. Med. Assoc. 246:1981;1942-1948.
8. Mufson M.A., Oley G., Hughey D. Pneumococcal disease in a medium-sized community in the US. J. Am. Med. Assoc. 248:1982;1486-1489.
9. Örtqvist A., Kalin M., Julander I., Mufson M.A. Deaths in bacteremic pneumococcal pneumonia - a comparison of two populations - Huntington, WV, and Stockholm, Sweden. Chest. 103:1993;710-716.
10. Örtqvist A., Kalin M. Bacteremic pneumococcal pneumonia in Stockholm, Sweden in 1984. Scand. J. Infect. Dis. 1988:20;451-452.
11. Stanek R.J., Mufson M.A. Emergence of penicillin-resistant invasive pneumococci in a single American community. Am. J. Med. Sci. 310:1995;150-155.
12. Hoefnagels-Schuermans A., Van Eldere J., Van Lierde S., Verbist L., Verhaegen J., Peetermans W.E. Increase in penicillin resistance rates in Belgium due to clonal spread of a penicillin-resistant 23F Streptococcus pneumoniae strain. Eur. J. Clin. Microbiol. Infect. Dis. 18:1999;120-125.
13. Ahman H., Kayhty H., Lehtonen H., Leroy O., Froeschle J., Eskola J. Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory. Pediatr. Infect. Dis. J. 17:1998;211-216.
14. Rennels M.B., Edwards K.M., Keyserling H.L., Reisinger K.S., Hogerman D.A., Madore D.V. et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in US infants. Pediatrics. 101:1998;604-611.
15. Sorensen R.U., Leiva L.E., Giangrosso P.A., Butler B., Javier F.C. III, Sacerdote D.M. et al. Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine. Pediatr. Infect. Dis. J. 17:1998;685-691.
16. Dagan R., Melamed R., Zamir O., Leroy O. Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens. Pediatr. Infect. Dis. J. 16:1997;1053-1059.
17. Mufson M.A., Hughey D., Lydick E. Type-specific antibody responses of volunteers immunized with 23-valent pneumococcal polysaccharide vaccine. J. Infect. Dis. 151:1985;749-750.
18. Cadoz M., Armand J., Arminjon F., Michel J.P., Michel M., Denis F. et al. A new 23 valent pneumococcal vaccine: immunogenicity and reactogenicity in adults. J. Biol. Stand. 13:1985;261-265.
19. Poland G.A. The burden of pneumococcal disease: the role of conjugate vaccines. Vaccine. 17:1999;1674-1679.
20. Sydnor T.A., Kopp E.J., Anthony K.E., LoCoco J.M., Kim S.S., Fowler C.L. Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults. Ann. Allergy Asthma Immunol. 80:1998;357-362.
21. Davidson M., Bulkow L.R., Grabman J., Parkinson A.J., Chamblee C., Williams W.W. et al. Immunogenicity of pneumococcal revaccination in patients with chronic disease. Arch. Intern. Med. 154:1994;2209-2214.
22. Mufson M.A., Hughey D.F., Turner C.E., Schiffman G. Revaccination with pneumococcal vaccine of elderly persons 6 years after primary vaccination. Vaccine. 9:1991;403-407.
23. Fattal-German M., Taillandier J., Mathieu D., Bizzini B. Pneumococcal vaccination of elderly individuals. Vaccine. 9:1991;542-544.
24. Roghmann K.J., Tabloski P.A., Bentley D.W., Schiffman G. Immune response of elderly adults to pneumococcus: variation by age, sex, and functional impairment. J. Gerontol. 42:1987;265-270.
25. Smit P., Oberholzer D., Hayden-Smith S., Koornhof H.J., Hilleman M.R. Protective efficacy of pneumococcal polysaccharide vaccines. J. Am. Med. Assoc. 238:1977;2613-2616.
26. Austrian R. Prevention of pneumococcal infection by immunization with capsular polysaccharides of Streptococcus pneumoniae: current status of polyvalent vaccines. J. Infect. Dis. 136:1977;S38-S42.
27. Broome C.V., Facklam R.R., Fraser D.W. Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine. New Engl. J. Med. 303:1980;549-552.
28. Gratten M., Gratten H., Poli A., Carrad E., Raymer M., Koki G. Colonisation of Haemophilus influenzae and Streptococcus pneumoniae in the upper respiratory tract of neonates in Papua New Guinea: primary acquisition, duration of carriage, and relationship to carriage in mothers. Biol. Neonate. 50:1986;114-120.
29. Kaufhold A., Lutticken R., Henrichsen J. Capsular types and antibiotic susceptibility of Streptococcus pneumoniae isolated from patients with systemic infections in West Germany. Eur. J. Clin. Microbiol. 6:1987;696-697.
30. Shapiro E.D., Berg A.T., Austrian R., Schroeder D., Parcells V., Margolis A. et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. New Engl. J. Med. 325:1991;1453-1460.
31. Rodriguez-Barradas M.C., Groover J.E., Lacke C.E., Gump D.W., Lahart C.J., Pandey J.P. et al. IgG antibody to pneumococcal capsular polysaccharide in human immunodeficiency virus-infected subjects: persistence of antibody in responders, revaccination in nonresponders, and relationship of immunoglobulin allotype to response. J. Infect. Dis. 173:1996;1347-1353.
32. Schiffman G., Douglas R.M., Bonner M.J., Robbins M., Austrian R. A radioimmunoassay for immunologic phenomena in pneumococcal disease and for the antibody response to pneumococcal vaccines. I. Method for the radioimmunoassay of anticapsular antibodies and comparison with other techniques. J. Immunol. Methods. 33:1980;133-144.
33. Landesman S.H., Schiffman G. Assessment of the antibody response to pneumococcal vaccine in high-risk populations. Rev. Infect. Dis. 3:1981;S184-S197.
34. Musher D.M., Luchi M.J., Watson D.A., Hamilton R., Baughn R.E. Pneumococcal polysaccharide vaccine in young adults and older bronchitics: determination of IgG responses by ELISA and the effect of adsorption of serum with non-type-specific cell wall polysaccharide. J. Infect. Dis. 161:1990;728-735.
35. Musher D.M., Watson D.A., Baughn R.E. Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infection? J. Infect. Dis. 161:1990;736-740.
36. Musher D.M., Johnson B. Jr, Watson D.A. Quantitative relationship between anticapsular antibody measured by enzyme-linked immunosorbent assay or radioimmunoassay and protection of mice against challenge with Streptococcus pneumoniae serotype 4. Infect. Immun. 58:1990;3871-3876.
37. Mufson M.A., Krause H.E., Schiffman G. Reactivity and antibody responses of volunteers given two or three doses of pneumococcal vaccine. Proc. Soc. Exp. Biol. Med. 177:1984;220-225.
38. Mufson M.A., Krause H.E., Schiffman G., Hughey D.F. Pneumococcal antibody levels one decade after immunization of healthy adults. Am. J. Med. Sci. 293:1987;279-284.
39. Gaillat J. Epidemiology of systemic Streptococcus pneumoniae infections. Presse Med. 27(1):1998;9-16.
40. Nielsen S.V., Henrichsen J. Incidence of invasive pneumococcal disease and distribution of capsular types of pneumococci in Denmark, 1989-1994. Epidemiol. Infect. 117:1996;411-416.
41. Hedlund J., Svenson S.B., Kalin M., Henrichsen J., Olsson-Liljequist B., Mollerberg G. et al. Incidence, capsular types, and antibiotic susceptibility of invasive Streptococcus pneumoniae in Sweden. Clin. Infect. Dis. 21:1995;948-953.
42. Musher D.M., Groover J.E., Rowland J.M., Watson D.A., Struewing J.B., Baughn R.E. et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination. Clin. Infect. Dis. 17:1993;66-73.
43. Rodriguez R., Dyer P.D. Safety of pneumococcal revaccination. J. Gen. Intern. Med. 10:1995;511-512.
44. Jackson L.A., Benson P., Sneller V.P., Butler J.C., Thompson R.S., Chen R.T. et al. Safety of revaccination with pneumococcal polysaccharide vaccine. J. Am. Med. Assoc. 281:1999;243-248.
45. Sankilampi U., Honkanen P.O., Bloigu A., Leinonen M. Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly. J. Infect. Dis. 176:1997;1100-1104.
46. Mufson M.A., Krause H.E., Schiffman G. Long-term persistence of antibody following immunization with pneumococcal polysaccharide vaccine. Proc. Soc. Exp. Biol. Med. 173:1983;270-275.
47. Nichol K.L. Revaccination of high-risk adults with pneumococcal polysaccharide vaccine. J. Am. Med. Assoc. 281:1999;280-281. , [editorial; comment].
48. Rodriguez-Barradas M.C., Musher D.M., Lahart C., Lacke C., Groover J., Watson D. et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23- valent pneumococcal vaccine. J. Infect. Dis. 165:1992;553-556.
49. Mufson M.A. Timing the pneumococcal vaccine: immunize sooner rather than later? J. Resp. Dis. 19:1999;614.